Global Methadone Market
Global Methadone Market

Methadone Comprehensive Study by Type (Oral Medicine (Tablets, Liquid), Injections), Application (Operation, Detoxification, Others) Players and Region - Global Market Outlook to 2024

Methadone Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

May 2019 Edition 219 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Methadone is a medicine used in Medication-Assisted Treatment (MAT) to help people reduce or quit their use of heroin or other opiates. It has been used for decades to treat people who are addicted to heroin and narcotic pain medicines. When methadone is taken as prescribed, it is safe and effective. Methadone allows people to recover from their addiction and to regain active and meaningful lives. For optimal results, patients should also participate in a comprehensive Medication-Assisted Treatment (MAT) program which includes counseling and social support.This growth is primarily driven by Rise in the Number of People Addicted to Various Opioid and Increasing Awareness about the Use of Methadone Medication.

Globally, a noticeable market trend is evident Growth in Number of People Seeking Help to Detox . Major Players, such as Qinghai Pharm (China), Roxane Laboratories, Inc. (United States), Centralpharm (China), Martindale Pharmaceuticals Limited (United Kingdom), Mallinckrodt (United Kingdom), Macfarlan Smith (United Kingdom), Vistapharm (United States), Aurolife Pharma Llc (United States), CRC Health Group (United States) and Paladin Labs Inc. (Canada) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Regulatory Insights:
Under the Federal Food, Drug, and Cosmetic Act, the Food and Drug Administration (FDA) in the Department of Health and Human Services (HHS) has primary responsibility for ensuring the safety and effectiveness of pharmaceuticals, regardless of whether they are controlled substances. Methadone, buprenorphine, and naltrexone are subject to the FFDCA.

Market Drivers
  • Rise in the Number of People Addicted to Various Opioid
  • Increasing Awareness about the Use of Methadone Medication

Market Trend
  • Growth in Number of People Seeking Help to Detox
  • Increase in the Number of People with Chronic Pain

Restraints
  • Side Effects Related to the Use of Methadone

Opportunities
Growing Healthcare Infrastructure in Developing Region
Challenges
Stringent Government Regulations

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Oral Medicine [Tablets, Liquid]
  • Injections
By Application
  • Operation
  • Detoxification
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the Number of People Addicted to Various Opioid
      • 3.2.2. Increasing Awareness about the Use of Methadone Medication
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Growth in Number of People Seeking Help to Detox
      • 3.4.2. Increase in the Number of People with Chronic Pain
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Methadone, by Type, Application and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Methadone (Value)
      • 5.2.1. Global Methadone by: Type (Value)
        • 5.2.1.1. Oral Medicine [Tablets, Liquid]
        • 5.2.1.2. Injections
      • 5.2.2. Global Methadone by: Application (Value)
        • 5.2.2.1. Operation
        • 5.2.2.2. Detoxification
        • 5.2.2.3. Others
      • 5.2.3. Global Methadone Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Methadone (Price)
      • 5.3.1. Global Methadone by: Type (Price)
  • 6. Methadone: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Qinghai Pharm (China)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roxane Laboratories, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Centralpharm (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Martindale Pharmaceuticals Limited (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mallinckrodt (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Macfarlan Smith (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Vistapharm (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Aurolife Pharma Llc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CRC Health Group (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Paladin Labs Inc. (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Methadone Sale, by Type, Application and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Methadone (Value)
      • 7.2.1. Global Methadone by: Type (Value)
        • 7.2.1.1. Oral Medicine [Tablets, Liquid]
        • 7.2.1.2. Injections
      • 7.2.2. Global Methadone by: Application (Value)
        • 7.2.2.1. Operation
        • 7.2.2.2. Detoxification
        • 7.2.2.3. Others
      • 7.2.3. Global Methadone Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Methadone (Price)
      • 7.3.1. Global Methadone by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Methadone: by Type(USD Million)
  • Table 2. Methadone Oral Medicine [Tablets, Liquid] , by Region USD Million (2013-2018)
  • Table 3. Methadone Injections , by Region USD Million (2013-2018)
  • Table 4. Methadone: by Application(USD Million)
  • Table 5. Methadone Operation , by Region USD Million (2013-2018)
  • Table 6. Methadone Detoxification , by Region USD Million (2013-2018)
  • Table 7. Methadone Others , by Region USD Million (2013-2018)
  • Table 8. South America Methadone, by Country USD Million (2013-2018)
  • Table 9. South America Methadone, by Type USD Million (2013-2018)
  • Table 10. South America Methadone, by Application USD Million (2013-2018)
  • Table 11. Brazil Methadone, by Type USD Million (2013-2018)
  • Table 12. Brazil Methadone, by Application USD Million (2013-2018)
  • Table 13. Argentina Methadone, by Type USD Million (2013-2018)
  • Table 14. Argentina Methadone, by Application USD Million (2013-2018)
  • Table 15. Rest of South America Methadone, by Type USD Million (2013-2018)
  • Table 16. Rest of South America Methadone, by Application USD Million (2013-2018)
  • Table 17. Asia Pacific Methadone, by Country USD Million (2013-2018)
  • Table 18. Asia Pacific Methadone, by Type USD Million (2013-2018)
  • Table 19. Asia Pacific Methadone, by Application USD Million (2013-2018)
  • Table 20. China Methadone, by Type USD Million (2013-2018)
  • Table 21. China Methadone, by Application USD Million (2013-2018)
  • Table 22. Japan Methadone, by Type USD Million (2013-2018)
  • Table 23. Japan Methadone, by Application USD Million (2013-2018)
  • Table 24. India Methadone, by Type USD Million (2013-2018)
  • Table 25. India Methadone, by Application USD Million (2013-2018)
  • Table 26. South Korea Methadone, by Type USD Million (2013-2018)
  • Table 27. South Korea Methadone, by Application USD Million (2013-2018)
  • Table 28. Taiwan Methadone, by Type USD Million (2013-2018)
  • Table 29. Taiwan Methadone, by Application USD Million (2013-2018)
  • Table 30. Australia Methadone, by Type USD Million (2013-2018)
  • Table 31. Australia Methadone, by Application USD Million (2013-2018)
  • Table 32. Rest of Asia-Pacific Methadone, by Type USD Million (2013-2018)
  • Table 33. Rest of Asia-Pacific Methadone, by Application USD Million (2013-2018)
  • Table 34. Europe Methadone, by Country USD Million (2013-2018)
  • Table 35. Europe Methadone, by Type USD Million (2013-2018)
  • Table 36. Europe Methadone, by Application USD Million (2013-2018)
  • Table 37. Germany Methadone, by Type USD Million (2013-2018)
  • Table 38. Germany Methadone, by Application USD Million (2013-2018)
  • Table 39. France Methadone, by Type USD Million (2013-2018)
  • Table 40. France Methadone, by Application USD Million (2013-2018)
  • Table 41. Italy Methadone, by Type USD Million (2013-2018)
  • Table 42. Italy Methadone, by Application USD Million (2013-2018)
  • Table 43. United Kingdom Methadone, by Type USD Million (2013-2018)
  • Table 44. United Kingdom Methadone, by Application USD Million (2013-2018)
  • Table 45. Netherlands Methadone, by Type USD Million (2013-2018)
  • Table 46. Netherlands Methadone, by Application USD Million (2013-2018)
  • Table 47. Rest of Europe Methadone, by Type USD Million (2013-2018)
  • Table 48. Rest of Europe Methadone, by Application USD Million (2013-2018)
  • Table 49. MEA Methadone, by Country USD Million (2013-2018)
  • Table 50. MEA Methadone, by Type USD Million (2013-2018)
  • Table 51. MEA Methadone, by Application USD Million (2013-2018)
  • Table 52. Middle East Methadone, by Type USD Million (2013-2018)
  • Table 53. Middle East Methadone, by Application USD Million (2013-2018)
  • Table 54. Africa Methadone, by Type USD Million (2013-2018)
  • Table 55. Africa Methadone, by Application USD Million (2013-2018)
  • Table 56. North America Methadone, by Country USD Million (2013-2018)
  • Table 57. North America Methadone, by Type USD Million (2013-2018)
  • Table 58. North America Methadone, by Application USD Million (2013-2018)
  • Table 59. United States Methadone, by Type USD Million (2013-2018)
  • Table 60. United States Methadone, by Application USD Million (2013-2018)
  • Table 61. Canada Methadone, by Type USD Million (2013-2018)
  • Table 62. Canada Methadone, by Application USD Million (2013-2018)
  • Table 63. Mexico Methadone, by Type USD Million (2013-2018)
  • Table 64. Mexico Methadone, by Application USD Million (2013-2018)
  • Table 65. Methadone: by Type(USD/Units)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Methadone: by Type(USD Million)
  • Table 77. Methadone Oral Medicine [Tablets, Liquid] , by Region USD Million (2019-2024)
  • Table 78. Methadone Injections , by Region USD Million (2019-2024)
  • Table 79. Methadone: by Application(USD Million)
  • Table 80. Methadone Operation , by Region USD Million (2019-2024)
  • Table 81. Methadone Detoxification , by Region USD Million (2019-2024)
  • Table 82. Methadone Others , by Region USD Million (2019-2024)
  • Table 83. South America Methadone, by Country USD Million (2019-2024)
  • Table 84. South America Methadone, by Type USD Million (2019-2024)
  • Table 85. South America Methadone, by Application USD Million (2019-2024)
  • Table 86. Brazil Methadone, by Type USD Million (2019-2024)
  • Table 87. Brazil Methadone, by Application USD Million (2019-2024)
  • Table 88. Argentina Methadone, by Type USD Million (2019-2024)
  • Table 89. Argentina Methadone, by Application USD Million (2019-2024)
  • Table 90. Rest of South America Methadone, by Type USD Million (2019-2024)
  • Table 91. Rest of South America Methadone, by Application USD Million (2019-2024)
  • Table 92. Asia Pacific Methadone, by Country USD Million (2019-2024)
  • Table 93. Asia Pacific Methadone, by Type USD Million (2019-2024)
  • Table 94. Asia Pacific Methadone, by Application USD Million (2019-2024)
  • Table 95. China Methadone, by Type USD Million (2019-2024)
  • Table 96. China Methadone, by Application USD Million (2019-2024)
  • Table 97. Japan Methadone, by Type USD Million (2019-2024)
  • Table 98. Japan Methadone, by Application USD Million (2019-2024)
  • Table 99. India Methadone, by Type USD Million (2019-2024)
  • Table 100. India Methadone, by Application USD Million (2019-2024)
  • Table 101. South Korea Methadone, by Type USD Million (2019-2024)
  • Table 102. South Korea Methadone, by Application USD Million (2019-2024)
  • Table 103. Taiwan Methadone, by Type USD Million (2019-2024)
  • Table 104. Taiwan Methadone, by Application USD Million (2019-2024)
  • Table 105. Australia Methadone, by Type USD Million (2019-2024)
  • Table 106. Australia Methadone, by Application USD Million (2019-2024)
  • Table 107. Rest of Asia-Pacific Methadone, by Type USD Million (2019-2024)
  • Table 108. Rest of Asia-Pacific Methadone, by Application USD Million (2019-2024)
  • Table 109. Europe Methadone, by Country USD Million (2019-2024)
  • Table 110. Europe Methadone, by Type USD Million (2019-2024)
  • Table 111. Europe Methadone, by Application USD Million (2019-2024)
  • Table 112. Germany Methadone, by Type USD Million (2019-2024)
  • Table 113. Germany Methadone, by Application USD Million (2019-2024)
  • Table 114. France Methadone, by Type USD Million (2019-2024)
  • Table 115. France Methadone, by Application USD Million (2019-2024)
  • Table 116. Italy Methadone, by Type USD Million (2019-2024)
  • Table 117. Italy Methadone, by Application USD Million (2019-2024)
  • Table 118. United Kingdom Methadone, by Type USD Million (2019-2024)
  • Table 119. United Kingdom Methadone, by Application USD Million (2019-2024)
  • Table 120. Netherlands Methadone, by Type USD Million (2019-2024)
  • Table 121. Netherlands Methadone, by Application USD Million (2019-2024)
  • Table 122. Rest of Europe Methadone, by Type USD Million (2019-2024)
  • Table 123. Rest of Europe Methadone, by Application USD Million (2019-2024)
  • Table 124. MEA Methadone, by Country USD Million (2019-2024)
  • Table 125. MEA Methadone, by Type USD Million (2019-2024)
  • Table 126. MEA Methadone, by Application USD Million (2019-2024)
  • Table 127. Middle East Methadone, by Type USD Million (2019-2024)
  • Table 128. Middle East Methadone, by Application USD Million (2019-2024)
  • Table 129. Africa Methadone, by Type USD Million (2019-2024)
  • Table 130. Africa Methadone, by Application USD Million (2019-2024)
  • Table 131. North America Methadone, by Country USD Million (2019-2024)
  • Table 132. North America Methadone, by Type USD Million (2019-2024)
  • Table 133. North America Methadone, by Application USD Million (2019-2024)
  • Table 134. United States Methadone, by Type USD Million (2019-2024)
  • Table 135. United States Methadone, by Application USD Million (2019-2024)
  • Table 136. Canada Methadone, by Type USD Million (2019-2024)
  • Table 137. Canada Methadone, by Application USD Million (2019-2024)
  • Table 138. Mexico Methadone, by Type USD Million (2019-2024)
  • Table 139. Mexico Methadone, by Application USD Million (2019-2024)
  • Table 140. Methadone: by Type(USD/Units)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Methadone: by Type USD Million (2013-2018)
  • Figure 5. Global Methadone: by Application USD Million (2013-2018)
  • Figure 6. South America Methadone Share (%), by Country
  • Figure 7. Asia Pacific Methadone Share (%), by Country
  • Figure 8. Europe Methadone Share (%), by Country
  • Figure 9. MEA Methadone Share (%), by Country
  • Figure 10. North America Methadone Share (%), by Country
  • Figure 11. Global Methadone: by Type USD/Units (2013-2018)
  • Figure 12. Global Methadone share by Players 2018 (%)
  • Figure 13. Global Methadone share by Players (Top 3) 2018(%)
  • Figure 14. Global Methadone share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Qinghai Pharm (China) Revenue, Net Income and Gross profit
  • Figure 17. Qinghai Pharm (China) Revenue: by Geography 2018
  • Figure 18. Roxane Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Roxane Laboratories, Inc. (United States) Revenue: by Geography 2018
  • Figure 20. Centralpharm (China) Revenue, Net Income and Gross profit
  • Figure 21. Centralpharm (China) Revenue: by Geography 2018
  • Figure 22. Martindale Pharmaceuticals Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Martindale Pharmaceuticals Limited (United Kingdom) Revenue: by Geography 2018
  • Figure 24. Mallinckrodt (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. Mallinckrodt (United Kingdom) Revenue: by Geography 2018
  • Figure 26. Macfarlan Smith (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. Macfarlan Smith (United Kingdom) Revenue: by Geography 2018
  • Figure 28. Vistapharm (United States) Revenue, Net Income and Gross profit
  • Figure 29. Vistapharm (United States) Revenue: by Geography 2018
  • Figure 30. Aurolife Pharma Llc (United States) Revenue, Net Income and Gross profit
  • Figure 31. Aurolife Pharma Llc (United States) Revenue: by Geography 2018
  • Figure 32. CRC Health Group (United States) Revenue, Net Income and Gross profit
  • Figure 33. CRC Health Group (United States) Revenue: by Geography 2018
  • Figure 34. Paladin Labs Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Paladin Labs Inc. (Canada) Revenue: by Geography 2018
  • Figure 36. Global Methadone: by Type USD Million (2019-2024)
  • Figure 37. Global Methadone: by Application USD Million (2019-2024)
  • Figure 38. South America Methadone Share (%), by Country
  • Figure 39. Asia Pacific Methadone Share (%), by Country
  • Figure 40. Europe Methadone Share (%), by Country
  • Figure 41. MEA Methadone Share (%), by Country
  • Figure 42. North America Methadone Share (%), by Country
  • Figure 43. Global Methadone: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Qinghai Pharm (China)
  • Roxane Laboratories, Inc. (United States)
  • Centralpharm (China)
  • Martindale Pharmaceuticals Limited (United Kingdom)
  • Mallinckrodt (United Kingdom)
  • Macfarlan Smith (United Kingdom)
  • Vistapharm (United States)
  • Aurolife Pharma Llc (United States)
  • CRC Health Group (United States)
  • Paladin Labs Inc. (Canada)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation